联合递送药物和基因的智能抗癌控释体系

发布时间：2018-05-01 23:31

本文选题：联合递送 + 药物　；参考：《化学进展》2017年05期

【摘要】：癌症是严重威胁人类健康和生命的重大疾病之一,目前化疗是临床癌症治疗的主要手段。但是由于癌症发病机制的复杂性和异质性,单一疗法通常无法有效地抑制癌症的发展和转移。因此,包含多种抗癌机制的联合疗法成为越来越重要的治疗策略。凭借其增强抗癌疗效和降低毒副作用的能力,联合递送药物和基因的纳米载体已经成为生物医药领域的研究热点。本文综述了联合递送药物和基因的智能抗癌控释载体的最新研究进展,分类介绍了这些联合递送载体的制备方法和作用机制,它们可在肿瘤微环境的刺激因素(如p H、谷胱甘肽和酶等)或者外源性刺激(如温度、超声等)作用下发生结构或构象的变化,从而实现了药物和基因的可控释放,产生协同治疗作用。此外,本文还对联合递送载体的发展前景作了展望。
[Abstract]:Cancer is one of the major diseases that threaten human health and life seriously. At present, chemotherapy is the main method of clinical cancer treatment. However, due to the complexity and heterogeneity of the pathogenesis of cancer, monotherapy can not effectively inhibit the development and metastasis of cancer. Therefore, combination therapy including various anticancer mechanisms has become an increasingly important therapeutic strategy. Because of its ability to enhance the anticancer effect and reduce the side effects, the combination delivery of drugs and genes has become a research hotspot in the field of biomedicine. In this paper, the latest research progress of intelligent anticancer and controlled-release vectors for drug and gene delivery is reviewed, and the preparation methods and mechanism of these carriers are introduced. They can undergo structural or conformational changes in tumor microenvironment stimuli (such as pH, glutathione and enzymes) or exogenous stimuli (such as temperature, ultrasound, etc.), thus enabling controlled release of drugs and genes. Have synergistic therapeutic effect. In addition, the prospect of joint delivery carrier is also prospected.
【作者单位】：南京理工大学化工学院;
【基金】：国家自然科学基金项目(No.51672133) 江苏省自然科学基金项目(No.BK20161496)资助~~
【分类号】：R73-36

【相似文献】